Full Press Release Details
Celldex Therapeutics Announces Proposed Public Offering of
HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) - Celldex
Therapeutics, Inc. ("Celldex" or the "Company") (Nasdaq: CLDX), today announced that it is proposing to
offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Celldex expects to
grant the underwriters a 30 day option to purchase up to an additional 15% of the shares of common stock offered in the public
offering. All of the shares of common stock are being offered by the Company. Celldex intends to use the net proceeds from the
offering to continue clinical and preclinical development of its product candidates and for general corporate purposes. The final
terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether
or when the offering may be completed, or as to the actual size or terms of the offering.
Cantor Fitzgerald & Co. is acting as the sole book running
manager for the offering.
The securities described above will be offered pursuant to
a shelf registration statement on Form S-3 (No. 333-235399), which was previously filed with and declared effective by the Securities
and Exchange Commission ("SEC") on June 12, 2020. A preliminary prospectus supplement and accompanying base
prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on
the SEC's website located at http://www.sec.gov, copies of which may be obtained, when available, from Cantor
Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by e-mail at prospectus@cantor.com.
This offering will be made only by means of a prospectus. This
press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein,
nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating
diseases for which available treatments are inadequate. Our pipeline includes immunotherapies and other targeted biologics derived
from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit
tumors to treat specific types of cancer or other diseases.
Forward Looking Statement
This release contains "forward-looking
statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These
statements are typically preceded by words such as "believes," "expects," "anticipates,"
"intends," "will," "may," "should," or similar expressions. These forward-looking
statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or
events. The offering is subject to market and other conditions and there can be no assurance as to whether or when the
offering may be completed or as to the actual size or terms of the offering or use of proceeds thereof. Although management
believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations
will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ
materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development
and commercialization of Company drug candidates; the effects of the outbreak of COVID-19 on our business and results of
operations; our ability to obtain additional capital to meet our long-term liquidity needs on acceptable terms, or at all,
including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to
initiate; our ability to maintain compliance with Nasdaq listing requirements; our ability to realize the cost benefits of
consolidating our office and laboratory space and to retain key personnel after that consolidation; our ability to realize
the anticipated benefits from the acquisition of Kolltan; the uncertainties inherent in clinical testing and accruing
patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to
manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products
at varying stages of development; the availability, cost, delivery and quality of clinical and commercial grade materials
produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the
timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to
continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key
personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the
Company's products; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly
reports on Form 10-Q.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak
only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct
any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Senior Vice President, Corporate Affairs & Administration
Celldex Therapeutics, Inc.
Source: Celldex Therapeutics, Inc.